BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX® (daratumumab) ...
RARITAN, N.J., May 26, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO ...
Findings showed treatment with D-VCd significantly improved MOD-PFS and OS vs treatment with VCd. The Food and Drug Administration (FDA) has granted traditional approval to Darzalex Faspro ® ...
SAN DIEGO — Final results of the phase 3 Andromeda study confirmed that adding daratumumab (DARA) — a human CD38-targeting monoclonal antibody — to bortezomib, cyclophosphamide, and dexamethasone (VCd ...
Findings showed treatment with D-VCd significantly improved MOD-PFS and OS vs treatment with VCd. The Food and Drug Administration (FDA) has granted traditional approval to Darzalex Faspro ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results